{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T14:29:24Z","timestamp":1764858564127,"version":"build-2065373602"},"reference-count":47,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"vor","delay-in-days":1642,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1016\/j.bbmt.2010.09.003","type":"journal-article","created":{"date-parts":[[2010,12,31]],"date-time":"2010-12-31T04:48:08Z","timestamp":1293770888000},"page":"S115-S122","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"S","title":["Controversies in the Treatment of CML in Children and Adolescents: TKIs versus BMT?"],"prefix":"10.1016","volume":"17","author":[{"given":"Meinolf","family":"Suttorp","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isaac","family":"Yaniv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirk R.","family":"Schultz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"1999","series-title":"Cancer incidence and survival among children and adolescents: United States SEER Program, 1975-1995. NIH Pub No. 99-4649","key":"10.1016\/j.bbmt.2010.09.003_bib1"},{"key":"10.1016\/j.bbmt.2010.09.003_bib2","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1111\/j.1365-2141.2005.05731.x","article-title":"Long-term follow-up of Philadelphia chromosome-positive (Ph) chronic myeloid leukaemia (CML) in children and adolescents managed at a single institution over a 20-year period","volume":"130","author":"Giona","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2010.09.003_bib3","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2010-03-273979","article-title":"Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the international randomized study of interferon and STI571 (IRIS)","author":"Hughes","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.09.003_bib4","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1182\/blood-2003-09-3032","article-title":"Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children\u2019s Oncology Group phase 1 study","volume":"104","author":"Champagne","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.09.003_bib5","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/sj.leu.2404051","article-title":"Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase, and in relapse after stem cell transplantation","volume":"20","author":"Millot","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2010.09.003_bib6","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood.V114.22.863.863","article-title":"Imatinib is efficient but has a negative impact on growth in children with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CP): results of the French national phase IV trial","volume":"114","author":"Millot","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.09.003_bib7","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/blood.V114.22.339.339","article-title":"Randomised comparison of imatinib 800 mg versus imatinib 400 mg \u00fe\/_ IFN in newly diagnosed BCR\/ABL positive chronic phase CML: analysis of molecular remissions at 12 months; the German CML Study IV. (ASH Annual Meeting abstract)","volume":"114","author":"Hehlmann","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.09.003_bib8","doi-asserted-by":"crossref","DOI":"10.1182\/asheducation-2010.1.368","article-title":"Treatment of pediatric chronic myeloid leukemia in the year 2010: use of tyrosine kinase inhibitors and stem cell transplantation","author":"Suttorp","year":"2010","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.bbmt.2010.09.003_bib9","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.beha.2009.09.008","article-title":"CML in pregnancy and childhood","volume":"22","author":"Apperley","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.bbmt.2010.09.003_bib10","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.3324\/haematol.2009.008359","article-title":"Longitudinal growth retardation in a prepuberal girl with chronic myeloid leukemia on long-term imatinib treatment","volume":"94","author":"Schmid","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2010.09.003_bib11","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1038\/leu.2009.150","article-title":"Imatinib mesylate causes growth plate closure in vivo","volume":"23","author":"Vandyke","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2010.09.003_bib12","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1182\/blood.V112.11.1100.1100","article-title":"Side effects on the heart and skeleton of growing mice attributed to chronic imatinib exposure (ASH Annual Meeting abstract)","volume":"112","author":"Suttorp","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.09.003_bib13","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1182\/blood-2009-08-237404","article-title":"Dysregulation of bone remodelling by imatinib mesylate","volume":"115","author":"Vandyke","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.09.003_bib14","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s12185-008-0251-8","article-title":"Growth deceleration in a girl treated with imatinib","volume":"89","author":"Kimoto","year":"2009","journal-title":"Int J Hematol"},{"key":"10.1016\/j.bbmt.2010.09.003_bib15","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0140-6736(08)61023-5","article-title":"Low bone density and decreased inhibin-B\/FSH ratio in a boy treated with imatinib during puberty","volume":"372","author":"Mariani","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2010.09.003_bib16","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1182\/blood.V114.22.342.342","article-title":"Chronic myeloid leukemia in pediatrics\u2014first results from study CML-PAED II (ASH Annual Meeting abstract)","volume":"114","author":"Suttorp","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.09.003_bib17","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.09.003_bib18","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2010.09.003_bib19","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2010.09.003_bib20","doi-asserted-by":"crossref","first-page":"15s","DOI":"10.1200\/jco.2010.28.15_suppl.tps281","article-title":"Phase II study of dasatinib in children and adolescents with newly diagnosed chronic phase chronic myelogenous leukemia (CP-CML) or Philadelphia-positive (Ph+) leukemias resistant or intolerant to imatinib. (Abstract ASCO Annual Meeting)","volume":"28","author":"Rosenberg","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.09.003_bib21","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/bmt.2008.252","article-title":"Efficacy of imatinib mesylate in the treatment of refractory sclerodermatous chronic GVHD","volume":"42","author":"Magro","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.09.003_bib22","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1182\/blood-2009-02-204156","article-title":"Imatinib for refractory chronic graft-versus-host disease with fibrotic features","volume":"114","author":"Olivieri","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.09.003_bib23","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1182\/blood.V114.22.859.859","article-title":"Discontinuation of Imatinib Therapy After Achieving a Molecular Response in Chronic Myeloid Leukemia Patients (ASH Annual Meeting abstract)","volume":"114","author":"Mahon","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.09.003_bib24","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1365-2141.2007.06582.x","article-title":"Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia","volume":"137","author":"Giralt","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2010.09.003_bib25","first-page":"S37","article-title":"A report from the EBMT Chronic Leukemia Working Party and the European Leukemia Group","volume":"41","author":"Heim","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.09.003_bib26","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1182\/blood-2009-08-237115","article-title":"Allogeneic hematopoietic stem cell transplantation (allo HCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV","volume":"115","author":"Saussele","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.09.003_bib27","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1200\/JCO.2009.26.7757","article-title":"Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase","volume":"28","author":"Goldman","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.09.003_bib28","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1182\/blood.V99.6.1971","article-title":"Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation","volume":"99","author":"Weisdorf","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.09.003_bib29","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/j.1365-2141.2004.04955.x","article-title":"Validation and extension of the EBMT Risk Score for patients with chronic myeloid leukaemia (CML) receiving allogeneic haematopoietic stem cell transplants","volume":"125","author":"Passweg","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2010.09.003_bib30","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1182\/blood-2002-12-3637","article-title":"Stem cell transplantation for chronic myeloid leukemia in children","volume":"102","author":"Cwynarski","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.09.003_bib31","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1055\/s-2008-1046480","article-title":"[Treatment of chronic myeloid leukemia in children and adolescents\u2014concept of the multicenter pilot study CML-ped.]","volume":"208","author":"Suttorp","year":"1996","journal-title":"Klin Padiatr"},{"key":"10.1016\/j.bbmt.2010.09.003_bib32","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/sj.bmt.1704255","article-title":"Allogeneic bone marrow transplantation for chronic myeloid leukemia in childhood: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC)","volume":"32","author":"Millot","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.09.003_bib33","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1080\/07853890801908903","article-title":"HLA-mismatched\/haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for chronic myeloid leukemia: improved outcomes in patients in accelerated phase and blast crisis phase","volume":"40","author":"Xiao-Jun","year":"2008","journal-title":"Ann Med"},{"key":"10.1016\/j.bbmt.2010.09.003_bib34","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1016\/j.molimm.2008.04.016","article-title":"KIR2DS5 is associated with leukemia free survival after HLA identical stem cell transplantation in chronic myeloid leukemia patients","volume":"45","author":"van der Meer","year":"2008","journal-title":"Mol Immunol"},{"key":"10.1016\/j.bbmt.2010.09.003_bib35","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1182\/blood-2004-09-3544","article-title":"Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT","volume":"106","author":"Crawley","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.09.003_bib36","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/sj.bmt.1705240","article-title":"Reduced intensity conditioning using intravenous busulfan, fludarabine and rabbit ATG for children with nonmalignant disorders and CML","volume":"37","author":"Horn","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.09.003_bib37","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.bbmt.2005.04.002","article-title":"Reduced-intensity allogeneic stem cell transplantation in adults and children with malignant and nonmalignant diseases: end of the beginning and future challenges","volume":"11","author":"Satwani","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.09.003_bib38","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1182\/blood.V96.8.2712","article-title":"Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia","volume":"96","author":"Dazzi","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.09.003_bib39","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1038\/sj.leu.2403068","article-title":"Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia","volume":"17","author":"Olavarria","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2010.09.003_bib40","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/pbc.22484","article-title":"Imatinib mesylate in children and adolescents with cancer","volume":"55","author":"Barr","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.bbmt.2010.09.003_bib41","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/bmt.2008.90","article-title":"Therapeutic choices in patients with Ph-positive CML living in Mexico in the tyrosine kinase inhibitor era: HCT or TKIs?","volume":"42","author":"Ruiz-Arguelles","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.09.003_bib42","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1038\/leu.2008.225","article-title":"A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials","volume":"22","author":"Lucas","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2010.09.003_bib43","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1182\/blood-2008-02-141689","article-title":"Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia","volume":"112","author":"Lee","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.09.003_bib44","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.bbmt.2009.09.022","article-title":"Outcome of 125 children with chronic myelogenous leukemia who received transplants from unrelated donors: the Japan Marrow Donor Program","volume":"16","author":"Muramatsu","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.09.003_bib45","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/j.exphem.2009.09.007","article-title":"Dasatinib inhibits the secretion of TNF-alpha following TLR stimulation in vitro and in vivo","volume":"37","author":"Fraser","year":"2009","journal-title":"Exp Hematol"},{"key":"10.1016\/j.bbmt.2010.09.003_bib46","doi-asserted-by":"crossref","first-page":"448","DOI":"10.3109\/08880010903071295","article-title":"Severe hemorrhagic colitis caused by dasatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"26","author":"Shimokaze","year":"2009","journal-title":"Pediatr Hematol Oncol"},{"key":"10.1016\/j.bbmt.2010.09.003_bib47","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.exphem.2008.09.013","article-title":"Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo","volume":"37","author":"Fraser","year":"2009","journal-title":"Exp Hematol"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879110003836?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879110003836?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:38:07Z","timestamp":1761057487000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879110003836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["S1083879110003836"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2010.09.003","relation":{},"ISSN":["1083-8791"],"issn-type":[{"type":"print","value":"1083-8791"}],"subject":[],"published":{"date-parts":[[2011,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Controversies in the Treatment of CML in Children and Adolescents: TKIs versus BMT?","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2010.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}